Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) EBT (2016 - 2025)

Historic EBT for Marker Therapeutics (MRKR) over the last 10 years, with Q3 2025 value amounting to -$2.0 million.

  • Marker Therapeutics' EBT rose 1341.01% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.4 million, marking a year-over-year decrease of 4917.25%. This contributed to the annual value of -$10.7 million for FY2024, which is 2393.4% up from last year.
  • Per Marker Therapeutics' latest filing, its EBT stood at -$2.0 million for Q3 2025, which was up 1341.01% from -$4.1 million recorded in Q2 2025.
  • Marker Therapeutics' EBT's 5-year high stood at -$2.0 million during Q3 2025, with a 5-year trough of -$9.8 million in Q1 2022.
  • For the 4-year period, Marker Therapeutics' EBT averaged around -$3.9 million, with its median value being -$3.8 million (2024).
  • As far as peak fluctuations go, Marker Therapeutics' EBT skyrocketed by 5685.27% in 2023, and later crashed by 8849.14% in 2025.
  • Marker Therapeutics' EBT (Quarter) stood at -$2.9 million in 2022, then grew by 6.58% to -$2.7 million in 2023, then plummeted by 38.42% to -$3.8 million in 2024, then skyrocketed by 47.23% to -$2.0 million in 2025.
  • Its last three reported values are -$2.0 million in Q3 2025, -$4.1 million for Q2 2025, and -$4.4 million during Q1 2025.